15 years old COVID-19 vaccine parents are absent.

Minors need to be accompanied by their parents for vaccination. People without parents won't call you.

Novel coronavirus vaccine (20 19-nCoVvaccine) is aimed at novel coronavirus. Up to February 25th, 20021year, four COVID-19 vaccines have been conditionally marketed in China, including three inactivated vaccines and one adenovirus vector vaccine.

On June 24th, 2020, China CDC successfully isolated the first novel coronavirus in China. At 20: 00 on March 16, the recombinant COVID-19 vaccine was allowed to start clinical trials. On April 13, China COVID-19 vaccine entered the phase II clinical trial; On the same day, an expert group composed of more than 20 scientists, doctors, funders and manufacturers from all over the world issued a public declaration, promising to work together to accelerate the research and development of vaccines in COVID-19 under the coordination of the World Health Organization. On June 19, the first COVID-19 mRNA vaccine in China was approved for clinical trial. 654381Oct 8, China signed an agreement with the Global Alliance for Vaccine Immunization and formally joined the "COVID-19 Vaccine Implementation Plan". 20021May 7, China COVID-19 vaccine was certified by WHO for emergency use; On June 1, China Kexing COVID-19 vaccine was authorized by WHO for emergency use.

Up to 202 1, 12, 19, 3 1 provinces (autonomous regions and municipalities directly under the central government) and Xinjiang production and construction corps reported 2,684.29 million doses of COVID-19 vaccine. By the end of 20021,12 and 16, the number of children aged 3-10/0 in China has exceeded10.40 billion.

2020122 October, it is reported that the University of Queensland is using a patented technology to rapidly produce a vaccine from novel coronavirus. Keith chapple of the University of Queensland, one of the leaders of the research project, told Xinhua that the research team of the university had obtained the gene sequence of novel coronavirus and was in the initial stage of developing related vaccines. The patented technology named "Molecular Tweezers" developed by the research team of the University of Queensland can increase the stability of the virus protein. The research team tried to use this technology to develop vaccines against Middle East respiratory syndrome coronavirus, Nipah virus, Ebola virus and influenza virus, and achieved very ideal experimental results.

On February 19, 2020, Sanofi Pasteur, the global vaccine division of Sanofi, announced that it would cooperate with BARDA and use the advanced gene recombination technology platform to accelerate the research and development of novel coronavirus vaccine.

On March 2, 2020, the University of California, Riverside, issued a statement saying that the research team discovered the drug target protein in COVID-19 and cracked the 3D structure of the protein, which will help to develop drugs for treating COVID-19. The research team consists of researchers from the University of California, Riverside, the University of Chicago, the Argon National Laboratory of the US Department of Energy and Northwestern University.

On April 7, 2020, an American company announced that the US Food and Drug Administration (FDA) had accepted its application for the new drug clinical trial (IND) of COVID-19 candidate DNA vaccine INO-4800.

On May 5, 2020, Pfizer began to test an experimental vaccine against COVID-19 in the United States.

On May 6, 2020, Pfizer, an American pharmaceutical giant, said that it had begun to test an experimental vaccine against COVID-19 in the United States. The first batch of subjects in the United States have been vaccinated with COVID-19 experimental vaccine BNT 162. The company is working with BioNTech, a German pharmaceutical manufacturer. In the first stage, the experiment will test the experimental vaccine for adults aged 65,438+08 to 55, and then turn to the elderly, hoping to test as many as 360 people.